Infographic.png (174.68 kB)

Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status

Version 2 2022-05-12, 11:11

Version 1 2022-05-12, 10:41

media

posted on 2022-05-12, 11:11 authored by Adis Rapid Journals on behalf of:, Qing Huang, Kathleen L Deering, Qing Harshaw, Lori A Leslie

The above infographic represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

History

Usage metrics

Keywords

chemoimmunotherapy chronic lymphocytic leukemia cytogenetics ibrutinib real-world evidence

Licence

CC BY-NC 4.0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM